Traduction de «screening before age 50 years » (Néerlandais → Français) :

24. Berrington de Gonzalez A, Reeves G. Mammographic screening before age 50 years in the UK: comparison of the radiation risks with the mortality benefits.
25. Berrington de Gonzalez A, Reeves G. Mammographic screening before age 50 years in the UK: comparison of the radiation risks with the mortality benefits.

16. Miller A, Baines C, Wall C. Canadian National Breast Screening Study-2: 13-year results of a randomized trial in women aged 50-59 years.
17. Miller A, Baines C, Wall C. Canadian National Breast Screening Study-2: 13-year results of a randomized trial in women aged 50-59 years.

Dépistage sein 2008 ( population cible 1x tous les 2 ans) Femmes âgées de 50 à 69 ans Femmes âgées de 40 à 49 ans % screening % Prog/tot nb moyen ex % screening Nb moyen ex Pop. totale 62% 48% 0,82 36% 0,61 Pop. M.G. 65% 48% 0,82 38% 0,62
Borstkankerscreening 2008 (doelgroep 1x om de 2 jaar) Vrouwen van 50 tot 69 jaar Vrouwen van 40 tot 49 jaar % screening % Prog/tot Gemiddeld aantal onderzoeken % screening Gemiddeld aantal onderzoeken

Gerard et al. Women from UK aged 40-64 (1999) 83 EQ-5D years (eligible for screening) UK tariffs (general population) True negative 0.940 At the breast screening Most women are nervous, but are not anxious or depressed. clinic
At the breast screening Most women are nervous, but are not anxious or depressed. Gerard et al. Women from UK aged 40-64

Table 8: Evidence form HTA review : Breast cancer screening among women aged 40 – 49 Relative risks (intention to treat) with confidence reported for each study together with the results of a stepwise meta-analysis and cumulative CI Study ID Relative risk Confidence interval Cumulative RR Cumutlative CI UK Age Trial (UK) 0,83 (0,66-1,04) 0,83 (0,66-1,04) NBSS-1 (Canada) 0,97 (0,74-1,27) 0,89 (0,75-1,06) Malmö (Sweden) (0,58-1,77) 0,9 (0,76-1,06) Stockholm (Sweden) 1,08 (0,54-2,17) 0,91 (0,77-1,07) Göteborg (Sweden) 0,65 (0,40-1,05) 0,87 (0,75-1,02) HIP (USA) 0,75 (0,50-1,11) 0,86 (0,74-0,99) TCS (Sweden) 0,93 (0,63-1,36) 0,86 (0,75-0,99) Edinburgh (UK) 0,75 (0.48-1,18) 0,85 (0,75-0,97)
Table 10: Evidence form HTA review : Breast cancer screening among women aged 40 – 49 Relative risks (intention to treat) with confidence reported for each study together with the results of a stepwise meta-analysis and cumulative CI Study ID Relative risk Confidence interval Cumulative RR Cumutlative CI UK Age Trial (UK) 0,83 (0,66-1,04) 0,83 (0,66-1,04) NBSS-1 (Canada) 0,97 (0,74-1,27) 0,89 (0,75-1,06) Malmö (Sweden) (0,58-1,77) 0,9 (0,76-1,06) Stockholm (Sweden) 1,08 (0,54-2,17) 0,91 (0,77-1,07) Göteborg (Sweden) 0,65 (0,40-1,05) 0,87 (0,75-1,02) HIP (USA) 0,75 (0,50-1,11) 0,86 (0,74-0,99) TCS (Sweden) 0,93 (0,63-1,36) 0,86 (0,75-0,99) Edinburgh (UK) 0,75 (0.48-1,18) 0,85 (0,75-0,97)

12. Ringash J. Preventive health care, 2001 update: screening mammography among women aged 40-49 years at average risk of breast cancer.
13. Ringash J. Preventive health care, 2001 update: screening mammography among women aged 40-49 years at average risk of breast cancer.

55. Mandelblatt J, Saha S, Teutsch S, Hoerger T, Siu AL, Atkins D, et al. The costeffectiveness of screening mammography beyond age 65 years: a systematic review for the U.S. Preventive Services Task Force.
54. Mandelblatt J, Saha S, Teutsch S, Hoerger T, Siu AL, Atkins D, et al. The costeffectiveness of screening mammography beyond age 65 years: a systematic review for the U.S. Preventive Services Task Force.

This approval was based on data showing Xolair reduced asthma attacks in this age group by 34% at 24 weeks and 50% at one year.
Cette autorisation repose sur des résultats montrant que Xolair réduisait les accès d’asthme chez ce groupe d’âges de 34% sur 24 semaines et de 50% sur un an.

56. Kerlikowske K, Salzmann P, Phillips KA, Cauley JA, Cummings SR. Continuing screening mammography in women aged 70 to 79 years: impact on life expectancy and cost-effectiveness.
55. Kerlikowske K, Salzmann P, Phillips KA, Cauley JA, Cummings SR. Continuing screening mammography in women aged 70 to 79 years: impact on life expectancy and cost-effectiveness.

Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK.
Guidelines for the diagnosis and manegement of osteoporosis in postmenopausal women and men from the age of 50 years in the UK.